Study finds link between racial factors and likelihood of getting proven diabetes treatment
Findings show Black, Asian, female and lower-income patients with diabetes receive less SGLT2 inhibitor treatment compared with overall trends
PHILADELPHIA-- A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania found significant disparities in the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs proven to treat type 2 diabetes, with usage remaining low with Black, Asian, and lower-income groups despite an increase in overall usage for patients with type 2 diabetes. The END